Loading...
Market
Number of new treatments announced by Agios by end of 2024?
5
Resolution / Starting Odds
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
Agios Pharmaceuticals official announcements
Story
$AGIO: Agios Pharmaceuticals Announces Positive Phase 3 Results for Mitapivat in Thalassemia, 30.4% vs. 12.6%
Jun 3, 2024, 10:34 AM
Agios Pharmaceuticals ($AGIO) has announced that its Phase 3 ENERGIZE-T study of Mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia met its primary endpoint and all key secondary endpoints. The study demonstrated a significant transfusion reduction response, with 30.4% of participants showing improvement compared to 12.6% in the placebo group. This positive outcome, announced on June 3, 2024, marks a potential novel advancement in care for patients with this inherited blood disorder.
View original story
Similar markets
None • 25%
1 • 25%
2 • 25%
3 or more • 25%
Acquisition • 33%
Partnership • 33%
None • 33%
None • 33%
One • 33%
Two or more • 34%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
Below $3 billion • 25%
$3-5 billion • 25%
$5-7 billion • 25%
Above $7 billion • 25%
No new approvals • 25%
1 new approval • 25%
2 new approvals • 25%
3 or more new approvals • 25%
0-5 • 25%
6-10 • 25%
11-20 • 25%
More than 20 • 25%